Medical disclaimer: The information in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Lab results and reference ranges vary by individual, lab, age, sex, and health history. Always consult a qualified healthcare provider before making any decisions about your health, medications, supplements, or lab testing. LabHealthCharts is a data visualization tool — it organizes and displays your lab data, it does not interpret your results or provide medical guidance.

What CoQ10 Actually Is

Coenzyme Q10 — often abbreviated as CoQ10 or ubiquinone — is a fat-soluble molecule the body synthesizes in nearly every cell. It sits inside the inner membrane of mitochondria, the structures that generate cellular energy, and shuttles electrons through the process that produces ATP (adenosine triphosphate, the fuel your cells run on). It also circulates in blood, mostly carried by LDL particles, where it functions as an antioxidant that protects lipids from oxidative damage.

In plain terms: CoQ10 is both a spark plug and a rust inhibitor for your cells. Without enough of it, energy production slows and oxidative stress rises. That combination is relevant to cardiovascular health, muscle function, and how several biomarkers on a standard lab panel behave.

The body makes CoQ10 from the amino acid tyrosine through a long enzymatic pathway that also requires vitamin B6, B12, and folate. Production peaks in your twenties and declines progressively with age. Certain medications — most notably statins — suppress the same enzyme pathway (HMG-CoA reductase) that CoQ10 synthesis depends on, which is why CoQ10 depletion is a well-documented concern in people on long-term statin therapy.

How CoQ10 Status Shows Up in Labs

There is no CoQ10 number on a standard metabolic panel or CBC. But CoQ10 status touches several markers that do appear on routine bloodwork. Understanding those connections helps you decide what to watch, and when a trend in one of those numbers might be worth discussing with your clinician.

Lipid Panel: LDL, Total Cholesterol, and Triglycerides

CoQ10 circulates largely bound to LDL particles. When total CoQ10 in blood is low, the antioxidant protection on those LDL particles is reduced, making them more susceptible to oxidation. Oxidized LDL is the form most associated with plaque formation in arterial walls.

Several randomized controlled trials have examined whether CoQ10 supplementation moves lipid numbers directly. A 2018 meta-analysis published in Lipids in Health and Disease pooled 17 trials and found CoQ10 supplementation significantly reduced total cholesterol (mean reduction ~11 mg/dL) and LDL cholesterol compared to placebo. Triglycerides also trended downward, though results varied by dose and baseline metabolic status.

So on your lipid panel, total cholesterol, LDL, and triglycerides are the numbers most likely to reflect any CoQ10-related change. HDL did not shift consistently across trials, which is typical for antioxidant and mitochondrial interventions that do not directly raise reverse cholesterol transport.

Glucose and Insulin: Metabolic Markers

Mitochondrial function is central to how cells handle glucose. When mitochondria are inefficient, insulin signaling degrades, and fasting glucose tends to creep upward over years. CoQ10 has been studied in people with type 2 diabetes and metabolic syndrome for this reason.

A 2020 meta-analysis in Complementary Medicine Research analyzed 13 RCTs and found that CoQ10 supplementation significantly lowered fasting glucose and HbA1c — glycated hemoglobin, the 90-day average blood sugar marker — in participants with metabolic disease. Effects were modest but consistent. HbA1c reductions averaged around 0.17–0.21%, which is meaningful alongside lifestyle changes.

For the reader: if your fasting glucose or HbA1c is trending toward the borderline range (fasting glucose 100–125 mg/dL, HbA1c 5.7–6.4%), these are the markers worth retesting after any meaningful change in diet, supplements, or activity level. CoQ10 status is one piece of a larger metabolic picture.

Blood Pressure: A Common Comorbidity Marker

Though blood pressure is not a blood test, it shows up on many lab visit forms and is tracked alongside cardiovascular biomarkers. A 2007 meta-analysis in the Journal of Human Hypertension found that CoQ10 supplementation reduced systolic blood pressure by a mean of 16.6 mmHg and diastolic by 8.2 mmHg across 12 clinical trials. The proposed mechanism is improved vascular endothelial function through reduced oxidative stress.

These are meaningful numbers — large enough to affect cardiovascular risk calculations — though researchers note that trial quality was mixed and results should be confirmed in larger, well-controlled studies. Systolic blood pressure is one reason many longevity-focused individuals track this reading alongside lipids, glucose, and inflammatory markers.

Liver Enzymes: ALT and AST in Statin Users

Statins occasionally elevate liver enzymes — alanine aminotransferase (ALT) and aspartate aminotransferase (AST) — and are associated with myopathy (muscle pain and weakness) in a meaningful minority of users. Because statins lower CoQ10 synthesis, some researchers have proposed that CoQ10 repletion may reduce muscle-related side effects.

Evidence here is mixed. A review in The American Journal of Cardiology found that some but not all CoQ10 supplementation trials showed reduction in statin-associated muscle symptoms. Liver enzyme elevations from statins are usually transient and do not consistently correlate with CoQ10 levels. Still, ALT and AST are worth monitoring as routine markers if you are on a statin, regardless of CoQ10 use.

Inflammation Markers: hsCRP and the Oxidative Stress Connection

High-sensitivity C-reactive protein (hsCRP) is a low-grade inflammation marker that predicts cardiovascular risk independently of LDL cholesterol. Values below 1.0 mg/L are considered low risk; 1.0–3.0 mg/L is moderate; above 3.0 mg/L is high risk in the absence of acute illness.

Because CoQ10 reduces oxidative stress on LDL and vascular tissue, some researchers hypothesize that it lowers hsCRP indirectly. A 2012 trial published in Pharmacological Research found significantly lower hsCRP levels in heart failure patients receiving CoQ10 supplementation versus placebo over 12 weeks. Effects in otherwise healthy adults are less certain.

The practical takeaway: hsCRP is worth including when you order a lipid or cardiovascular panel. If it is elevated and your lipids are already managed, inflammation itself is the remaining modifiable target — and CoQ10's antioxidant role is one of several evidence-informed levers being studied.

Who Has the Lowest CoQ10 Status (and What Labs Reflect That)

Natural depletion follows a predictable pattern. People over 50, those on statins, people with heart failure, and individuals with diabetes or metabolic syndrome consistently show lower plasma CoQ10 in population studies. Plasma CoQ10 can be measured directly (typically as a specialty or add-on test, not a standard panel), but the reference range varies considerably by lab and assay method — typically 0.4–1.9 mcg/mL in healthy adults, though values above 1.0 mcg/mL are generally considered more favorable.

Rather than ordering plasma CoQ10 as a standalone test, most clinicians focus on the downstream markers: lipids, fasting glucose, HbA1c, hsCRP, liver enzymes, and blood pressure. Those numbers reflect the functional consequences of mitochondrial and antioxidant status far more clearly than a single CoQ10 level — and they are already on standard annual panels.

Ubiquinone vs Ubiquinol: Does It Change the Lab Equation?

CoQ10 exists in two main forms: ubiquinone (oxidized, the form in most supplements) and ubiquinol (reduced, the active antioxidant form that circulates in blood). After age 40, the body's ability to convert ubiquinone to ubiquinol decreases. Ubiquinol supplements achieve higher plasma concentrations at the same dose in older adults, according to comparative bioavailability studies.

For lab tracking purposes, this distinction matters primarily because plasma CoQ10 tests measure total ubiquinol in blood. If you are monitoring plasma CoQ10 directly, the form of supplement may affect what you see. For the downstream biomarkers — lipids, glucose, hsCRP — trial data does not yet show a clear superiority of one form over the other in terms of clinical outcomes. Discuss the form with your provider if you are specifically trying to raise a measured plasma level.

Putting It Together: A Practical Lab Panel for CoQ10 Context

Biomarkers relevant to CoQ10 status and the evidence for each connection

Biomarker	Why It Matters Here	Direction of Evidence	Notes
LDL cholesterol (mg/dL)	CoQ10 circulates on LDL; oxidized LDL rises when CoQ10 is low	Moderate: reductions seen in meta-analyses	Effect size varies by baseline and dose
Total cholesterol (mg/dL)	Moves with LDL in most CoQ10 supplementation trials	Moderate: ~11 mg/dL mean reduction in meta-analysis	Reviewed 2018, 17 RCTs
Triglycerides (mg/dL)	Trended lower in several trials; mechanism less direct	Mixed: inconsistent across populations	Watch alongside diet changes
Fasting glucose (mg/dL)	Mitochondrial efficiency affects insulin sensitivity	Moderate in metabolic disease; less clear in healthy adults	Most data in T2D or metabolic syndrome
HbA1c (%)	90-day glucose average; improved in CoQ10 RCTs	Modest but consistent reductions (~0.17–0.21%)	More relevant with borderline values
hsCRP (mg/L)	Indirect via reduced oxidative stress and vascular inflammation	Preliminary; strongest in heart failure data	Useful cardiovascular risk marker regardless
ALT / AST (U/L)	Relevant in statin users where CoQ10 depletion occurs	Statin-muscle data mixed; monitor routinely	Elevations usually transient; discuss with provider
Plasma CoQ10 (mcg/mL)	Direct measure; specialty add-on test	Typically 0.4–1.9 mcg/mL; varies by lab and method	Not standard; request specifically if needed

A single blood draw gives you one data point for each of these numbers. What matters more — especially for a supplement like CoQ10 where changes are gradual and modest — is the direction over time. A lipid panel that drifts from borderline to in-range over six months, alongside a falling hsCRP and a stable fasting glucose, tells a meaningfully different story than any individual result.

CoQ10, Cardiac Health, and a Note on Heart Failure

The strongest clinical evidence for CoQ10 comes from the Q-SYMBIO trial, a multicenter, double-blind RCT published in JACC: Heart Failure. Researchers enrolled 420 patients with moderate-to-severe heart failure and randomized them to 300 mg/day CoQ10 or placebo for two years. The CoQ10 group showed significantly fewer major adverse cardiovascular events (15% vs 26%), lower cardiovascular mortality, and lower all-cause mortality.

This is one trial in a specific, high-risk population — not a general prevention study. But the mechanism is logical: heart muscle has the highest mitochondrial density and energy demand of any tissue, so it is most sensitive to CoQ10 depletion. People managing heart failure should discuss CoQ10 with their cardiologist and monitor BNP (B-type natriuretic peptide, a cardiac stress marker), alongside standard cardiology labs, at regular intervals.

Tracking CoQ10-Related Biomarkers Over Time with LabHealthCharts

The challenge with a supplement like CoQ10 is that its effects are slow, modest, and spread across several markers — lipids, glucose, inflammation. No single lab visit answers the question of whether it is doing anything for you. What you need is a timeline of at least two or three panels, each capturing the same set of markers, so you can see direction rather than a point-in-time snapshot.

LabHealthCharts is built exactly for that kind of longitudinal view. You upload lab PDFs from Quest, LabCorp, or any other format, and the app's AI-assisted extraction pulls your biomarker values into structured data automatically. From there, 100+ markers — including LDL, total cholesterol, triglycerides, HbA1c, fasting glucose, ALT, AST, and hsCRP — are charted on a shared timeline so you can see how each one moves across visits. That is far more informative than comparing two printed reports side by side or trying to remember what your LDL was 18 months ago.

If you are on a statin, tracking ALT, AST, and your lipid panel together over time lets you see whether muscle or liver markers move in ways your clinician should know about — and whether lipid control is holding. If you are monitoring metabolic health, watching HbA1c and fasting glucose across multiple draws tells a richer story than any single value. You can upload your labs and chart these markers over time with a $79/year LabHealthCharts membership — no per-report fees, and your full history stays in one place.

LabHealthCharts organizes and visualizes your lab data. It does not interpret your results or tell you whether CoQ10 is working for you — that conversation belongs with your clinician, who can weigh your full history. The app gives both of you a cleaner picture to have that conversation from. For more on the longevity-adjacent biomarkers most relevant to cardiovascular and metabolic health, see the longevity and anti-aging supplement page on CoQ10 or explore NAD+ precursors and the labs to watch for a related mitochondrial angle.

Key Takeaways

CoQ10 is a mitochondrial electron carrier and fat-soluble antioxidant that declines with age and is suppressed by statins. Its effects on lab markers are real but modest and spread across multiple panels.

The biomarkers most worth watching if you are interested in CoQ10 status: LDL and total cholesterol, triglycerides, fasting glucose, HbA1c, hsCRP, and liver enzymes (ALT/AST) if you are on a statin. Plasma CoQ10 can be measured directly as a specialty test, but most clinicians track downstream markers instead.

The strongest clinical evidence for CoQ10 comes from heart failure research, particularly the Q-SYMBIO trial. Evidence in otherwise healthy adults is promising but more modest — consistent with what you would expect from a mitochondrial support compound rather than a drug.

If you are evaluating CoQ10 supplementation, plan for at least two panels six months apart covering lipids, HbA1c, and hsCRP. Retest timing with your provider, not a single value, is where the real signal lives. And if you are on a statin, include ALT and AST at each visit as standard practice regardless of any supplement use.